{
    "code": "02022208",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02022208",
    "time": "2018-01-26 03:28:22",
    "許可證字號": "衛署藥輸字第022208號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "107\/06\/11",
    "發證日期": "87\/06\/11",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202220800",
    "中文品名": "癲通錠２００毫克",
    "英文品名": "TEGRETOL TABLETS 200MG",
    "適應症": "癲癇症、三叉神經痛、腎原性尿崩症、雙極性極患、原發性舌咽神經痛。",
    "劑型": "110錠劑",
    "包裝": "20-1000錠 (SBC, Super Triplex)PVC\/PE\/PVDC鋁箔盒裝",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "主成分略述": [
        "CARBAMAZEPINE"
    ],
    "限制項目": "02輸　入 1D須執行風險管理計畫",
    "申請商名稱": "1422701100  台灣諾華股份有限公司",
    "主製造廠": {
        "主製造廠": "",
        "製造廠名稱": "F250320000  NOVARTIS FARMA S.P.A.",
        "製造廠廠址": "VIA PROVINCIALE SCHITO 131, 80058 TORRE ANNUNZIATA, ITALY",
        "製造廠公司地址": ""
    },
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "2812000400",
            "成分名稱": "CARBAMAZEPINE",
            "含量描述": "",
            "含量": "200.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "(Final) Tegretol_IPL-11-07-17_TWI-161117_TFDA-106-11-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022208&Seq=004&Type=9"
        },
        {
            "title": "Tegretol 200mg_site-104-12-25(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022208&Seq=003&Type=8"
        }
    ]
}